PITTSBURGH, Nov. 6 /PRNewswire-FirstCall/ -- Mylan Inc.'s (NYSE: MYL) specialty business, Dey L.P., announced today that the Centers for Medicare & Medicaid Services (CMS) has established a unique billing code, or J-code, for Perforomist^™ Inhalation Solution, which is a product that was approved by the U.S. Food and Drug Administration in 2007 for long-term, twice-daily maintenance treatment of bronchoconstriction in patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema.

Carolyn Myers, Ph.D., president of Mylan's Specialty Division, commented: "While anticipated, we are very pleased that CMS has issued a J-code for Perforomist Inhalation Solution. The code will ease the reimbursement process for Perforomist and expand access to the many COPD patients who rely on healthcare coverage through Medicare," said Myers.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.

SOURCE Mylan Inc. 11/06/2008 /CONTACT: Media, Michael Laffin, +1-724-514-1968, or Investors, Dan Crookshank, +1-724-514-1813, both of Mylan Inc. /Web site: http://www.mylan.com (MYL)